D-Pharm LTD., a drug-development company, focuses on the development of drugs for the treatment of central nervous system conditions. Its pipeline of products comprise DP-VPA, a generic anti-epileptic drug, which has completed the Phase II clinical-stage trial for the treatment of various seizures, as well as for the treatment of manic depression and prophylaxis of migraine; and THR-18, a thrombolytic drug, which is in the Phase II clinical development for treatment of patients with acute ischemic stroke. The company is also developing DP-b99, which is in the Phase II clinical stage of development for the treatment of acute high-risk pancreatitis; and DP-NDD, a novel platform technology for disease-modifying drugs for the treatment of protein-misfolding neurodegenerative disorders, such as Alzheimer’s disease and other types of dementia, Parkinson’s disease, amyotrophic lateral sclerosis, and Huntington's disease. D-Pharm LTD. was founded in 1993 and is based in Rehovot, Israel.
(DPRM:Tel Aviv Stock Exchange)
Kiryat Weizmann Science Park
PO Box 2313
Phone: 972 8 938 5100
Fax: 972 8 930 0795www.dpharm.com
|No competitor information is available for DPRM.|
|View Industry Companies|
|Price/Cash Flow||--||Not Meaningful|
Sponsored Financial Commentaries
To contact D-PHARM LTD, please visit www.dpharm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.